• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Selecta Biosciences to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2022 Financial Results and Provide Business Update

    2/23/23 8:00:00 AM ET
    $SELB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SELB alert in real time by email

    WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today announced that it plans to host a conference call on Thursday, March 2, 2023, at 8:30 a.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2022 and provide a business update.

    Individuals may participate in the live call via telephone by dialing (844) 845-4170 (domestic) or (412) 717-9621 (international) and may access a teleconference replay for one week by dialing (877) 344-7529 (domestic) or (412) 317-0088 (international) and using confirmation code 8768458. Investors and the public can access the live and archived webcast of this call and a copy of the presentation via the Investors & Media section of the company's website, www.selectabio.com.

    About Selecta Biosciences, Inc.

    Selecta Biosciences Inc. (NASDAQ:SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body's natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.

    For Investors:

    Bruce Mackle

    LifeSci Advisors, LLC

    +1-929-469-3859

    [email protected]

    For Media: 

    Brittany Leigh, Ph.D.

    LifeSci Communications, LLC

    +1-646-751-4366

    [email protected]



    Primary Logo

    Get the next $SELB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SELB

    DatePrice TargetRatingAnalyst
    8/18/2023$1.00Outperform → Market Perform
    SVB Securities
    6/14/2022$6.00 → $5.00Buy
    Needham
    6/6/2022$7.00Outperform
    SVB Leerink
    11/1/2021$6.00 → $7.00Buy
    Needham
    More analyst ratings

    $SELB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Selecta Biosciences downgraded by SVB Securities with a new price target

      SVB Securities downgraded Selecta Biosciences from Outperform to Market Perform and set a new price target of $1.00

      8/18/23 7:37:44 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on Selecta Biosciences with a new price target

      Needham reiterated coverage of Selecta Biosciences with a rating of Buy and set a new price target of $5.00 from $6.00 previously

      6/14/22 7:48:06 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink initiated coverage on Selecta Biosciences with a new price target

      SVB Leerink initiated coverage of Selecta Biosciences with a rating of Outperform and set a new price target of $7.00

      6/6/22 7:48:05 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SELB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Singer Michael was granted 178,000 units of Common Stock, increasing direct ownership by 162% to 288,123 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      1/4/24 5:12:27 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Davis Blaine was granted 2,424,000 units of Common Stock (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      1/4/24 5:08:29 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jewell Christopher M was granted 778,200 units of Common Stock (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      1/4/24 5:08:06 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care